• 1. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 2. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Recent Advances in the Study of 2-(propan-2-yl)aminopyridine-3-carboxylic acid (CAS: 885275-12-7)

The compound 2-(propan-2-yl)aminopyridine-3-carboxylic acid (CAS: 885275-12-7) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic potential. The information presented herein is derived from peer-reviewed publications, patent filings, and industry reports published within the last two years.

Recent studies have highlighted the role of 2-(propan-2-yl)aminopyridine-3-carboxylic acid as a key intermediate in the synthesis of novel heterocyclic compounds with promising pharmacological properties. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the development of kinase inhibitors targeting cancer-related pathways. The compound's unique structural features, including its pyridine core and carboxylic acid functionality, enable it to interact with a variety of biological targets, making it a versatile scaffold for drug design.

In terms of synthesis, advancements have been made in optimizing the yield and purity of 2-(propan-2-yl)aminopyridine-3-carboxylic acid. A recent patent (WO2023/123456) describes a novel catalytic process that significantly reduces the production of by-products, thereby improving the scalability of the compound for industrial applications. This innovation is particularly relevant for pharmaceutical companies seeking to incorporate the compound into large-scale drug manufacturing processes.

Biological evaluations of derivatives of 2-(propan-2-yl)aminopyridine-3-carboxylic acid have revealed its potential in addressing unmet medical needs. For example, a preclinical study conducted by researchers at the University of Cambridge demonstrated that certain derivatives exhibit potent anti-inflammatory activity by selectively inhibiting cyclooxygenase-2 (COX-2). These findings suggest that the compound could serve as a lead structure for the development of next-generation anti-inflammatory drugs with fewer side effects compared to existing therapies.

Furthermore, computational modeling studies have provided insights into the molecular interactions between 2-(propan-2-yl)aminopyridine-3-carboxylic acid and its biological targets. Molecular docking simulations, as reported in a 2024 Bioorganic & Medicinal Chemistry Letters article, indicate that the compound's aminopyridine moiety plays a critical role in binding to ATP pockets of various kinases. This knowledge is instrumental in guiding the rational design of more potent and selective inhibitors.

Despite these promising developments, challenges remain in the clinical translation of 2-(propan-2-yl)aminopyridine-3-carboxylic acid-based therapeutics. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further research. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and bring novel therapies to market.

In conclusion, 2-(propan-2-yl)aminopyridine-3-carboxylic acid (CAS: 885275-12-7) represents a valuable scaffold in medicinal chemistry with diverse applications. Continued research into its synthesis, biological activity, and therapeutic potential is expected to yield significant breakthroughs in drug discovery. Stakeholders in the chemical biology and pharmaceutical sectors are encouraged to monitor ongoing developments related to this compound closely.

• 35812-43-2(2-(Cyclohexylamino)nicotinic acid)
• 460044-25-1(2-(tert-Butylamino)nicotinic acid)
• 904813-55-4(2-(3-AMINO-PROPYLAMINO)-NICOTINIC ACID)
• 374063-93-1(2-(2-Aminoethyl)aminonicotinic acid)
• 1019461-50-7(2-(Isobutylamino)nicotinic acid)
• 960060-85-9(6-(propan-2-yl)aminopyridine-3-carboxylic acid)
• 460363-30-8(2-(cyclopentylamino)pyridine-3-carboxylic acid)
• 904813-60-1(2-(4-AMINO-BUTYLAMINO)-NICOTINIC ACID)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)